Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
EnviroGold Closes Upsized Unit Offering Raising $4.1M and Announces New Director (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Solid Biosciences Inc SLDB

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3... see more

Recent & Breaking News (NDAQ:SLDB)

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

GlobeNewswire 22 hours ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 7 days ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

GlobeNewswire 8 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 10 days ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

GlobeNewswire December 23, 2024

Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

GlobeNewswire December 4, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2024

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire November 26, 2024

Solid Biosciences to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 14, 2024

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire November 6, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2024

Solid Biosciences to Participate at the Truist Securities BioPharma Symposium

GlobeNewswire October 31, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2024

Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference

GlobeNewswire September 23, 2024

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 12, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 4, 2024

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire September 4, 2024

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 13, 2024

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 5, 2024

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 1, 2024